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Summary. Background: Nitric oxide (NO) is a critical negative regulator of platelets implicated in the 
pathology of thrombotic diseases. Platelets generate NO but the presence and functional significance 
of NO synthase (NOS) in platelets is unclear. Inorganic nitrate/nitrite is increasingly recognised as a 
source of bioactive NO although its role in modulating platelets during health and vascular 
dysfunction is incompletely understood. Methods: We investigated the functional significance and 
upstream sources of NO-cGMP signalling events in platelets using established methods for assessing 
in vitro and in vivo platelet aggregation and assessed bioconversion of inorganic nitrate to nitrite 
during deficiency of endothelial NOS (eNOS). Results: The phosphodiesterase 5 (PDE5) inhibitor 
sildenafil inhibited human platelet aggregation in vitro. This inhibitory effect was abolished by a 
guanylyl cyclase inhibitor and NO scavengers but unaffected by NOS inhibition. Inorganic nitrite 
drove cGMP-mediated inhibition of human platelet aggregation in vitro and nitrate inhibited platelet 
function in eNOS-/- mice in vivo in a model of thromboembolic radiolabelled platelet aggregation 
associated with enhanced plasma nitrite concentration compared to wild-type mice. Conclusions: 
Platelets generate transient, endogenous cGMP signals downstream of NO that are primarily 
independent of NOS and may be enhanced by inhibition of PDE5. Furthermore, nitrite can generate 
transient NO-cGMP signals in platelets. The absence of eNOS leads to enhanced plasma nitrite levels 
following nitrate administration in vivo which negatively impacts platelet function. Our data suggest 
that inorganic nitrate exerts an antiplatelet effect during eNOS deficiency and, potentially, that 
dietary nitrate may reduce platelet hyperactivity during endothelial dysfunction. 
 
Keywords: nitric oxide, nitrites, pharmacology, platelets, thrombosis, 
Introduction 
Platelet activation is governed by a variety of positive and negative stimuli that act to precisely 
regulate the process of haemostasis. Positive stimulators of platelets include subendothelial collagen, 
thrombin generated via the coagulation cascade as well as ADP and thromboxane A2 which are 
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released from platelets themselves. The major negative regulators of platelets are prostacyclin (PGI2) 
and nitric oxide (NO), generated by the vascular endothelium. An imbalance between positive and 
negative platelet stimuli contributes to the pathogenesis of thrombotic disorders such as myocardial 
infarction. NO is conventionally described as being generated by NO synthase (NOS) enzymes which 
catalyse the conversion of L-arginine to L-citrulline resulting in NO release [1]. Many of the effects of 
NO are mediated through activation of soluble guanylyl cyclase (sGC), subsequent cGMP production 
and protein kinase activation leading to further signalling events including phosphorylation of the 
vasodilator-stimulated phosphoprotein (VASP).  The actions of cGMP are terminated by 
phosphodiesterase 5 (PDE5) which hydrolyses active cGMP to inactive GTP. PDE5 is expressed at high 
levels in platelets so that the effects of cGMP are transient due to its rapid hydrolysis. PDE5 
inhibitors, such as sildenafil citrate are used therapeutically in conditions associated with regional 
blood flow deficiency such as erectile dysfunction and pulmonary arterial hypertension. Sildenafil 
was reportedly associated with adverse cardiovascular events [2], however risk was more recently 
shown to arise from the cardiovascular risk profile of patients with erectile dysfunction  [3]. Focus 
can therefore shift towards exploration of PDE5 inhibition in cardioprotection [3]. Sildenafil has also 
been shown to enhance NO-mediated inhibition of human aggregation in vitro [4] and to enhance 
collagen-induced aggregation ex vivo [5]. The ability of sildenafil to directly modulate platelet 
activation in the absence of exogenous or endothelial NO by investigating its effect upon isolated 
platelets in vitro is poorly understood although it had no effect on ADP-induced aggregation in 
platelet-rich plasma [6]. 
 Endogenous NO derived from endothelial NOS (eNOS) in the vascular endothelium acts as a critical 
negative regulator of platelet function in vivo [7, 8] and deficiency of eNOS is associated with 
endothelial dysfunction and the pathology of a range of cardiovascular diseases [9, 10]. The intrinsic 
expression of eNOS in platelets remains contentious however [11, 12] and a number of studies have 
reported a lack of eNOS protein or mRNA in platelets as well as a lack of a functional role of platelet-
derived NO [13, 14]. There is, however, considerable evidence that platelets generate NO [15, 16] so 
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that the source of endogenous NO in platelets is unclear. More recently, NO has been shown to be 
derived not only via NOS but via reduction of inorganic nitrite [17]. In humans, dietary nitrate is 
concentrated and secreted by the salivary glands and reduced to nitrite by anaerobic bacteria on the 
tongue [18, 19]. Nitrite is absorbed into the circulation and is chemically reduced to NO by a variety 
of mechanisms including enzymatic processes that provide a mechanism for the localised delivery of 
NO to cells independent of NO synthases [17, 20]. Oral administration of nitrate lowered blood 
pressure [21] and modestly reduced platelet aggregation ex vivo in healthy volunteers [22] 
demonstrating the potential value of inorganic nitrate as a modulator of cardiovascular function. The 
ability of nitrate/nitrite to impact platelets in the context of endothelial dysfunction in vivo is 
unknown. 
We hypothesised that platelets generate transient NO-cGMP signals from upstream nitrate/nitrite. 
These signals may be amplified by PDE5 inhibition to reveal endogenous inhibitory signalling 
processes. Secondly, we hypothesised that during endothelial dysfunction, exogenously administered 
inorganic nitrate acts as an alternative source of bioactive NO to counteract impaired eNOS activity 
by inhibiting platelet activation following bioconversion to nitrite. 
 
Materials and methods 
Materials 
Materials used were as follows: 111indium oxine (GE Healthcare, Amersham, UK); collagen (Takeda 
Pharmaceuticals International, Linz, Austria); anti-vasodilator-stimulated phosphoprotein (VASP) and 
anti-VASP-P(Ser239) (Cell Signalling, Hertforshire, UK); iloprost (Cayman Chemicals, Washington, 
USA); Anti-rabbit horseradish peroxidase-conjugated antibody (Dako, Cambridgeshire, UK); anti-
GAPDH (Santa Cruz, California, USA). Sildenafil citrate was kindly donated by Pfizer (Peapack, NJ, 
USA). All other materials were purchased from Sigma-Aldrich (Poole, UK). 
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Light transmission aggregometry 
Blood was taken into ACD (1:9) from aspirin-free volunteers aged 23 to 55 years and with an even sex 
distribution. Informed consent from all blood donors was obtained and procedures were approved 
by the National Research Ethics Service. Platelet-rich plasma (PRP) was prepared by centrifugation at 
100 g for 20 mins. Washed platelets (WP) were prepared by the addition of ACD (1:80) and PGE1 (175 
nM) to PRP and centrifuged at 1400 g for 10 mins. The pellet was resuspended in tyrodes-HEPES 
buffer and the final centrifugation step was repeated. WP were resuspended to a platelet count of 
250x103 µL-1 in tyrodes-HEPES buffer. Platelet preparations were incubated for 5 mins with test 
compounds prior to stimulation with agonists and aggregation was measured at 37°C under stirring 
conditions in an optical aggregometer (Chrono-log Corporation, Havertown, USA).  
 
Western blotting 
Human WP were incubated with test compounds (as detailed for light transmission aggregometry) 
before centrifugation and pellet resuspension in RIPA lysis buffer. Western blotting was performed as 
detailed [23]. The antibody concentrations used were: rabbit anti-GAPDH (1:500), VASP (1:1000) and 
phosphor-VASP(Ser239) (1:1000) and incubations were at 4°C overnight. 
 
Nitrate/nitrite colorimetric assay 
Human washed platelets (500µL) were incubated in the presence or absence of test compounds for 5 
mins before they were snap frozen and stored at -80°C. Nitrate/nitrite concentration was determined 
in supernatants using a nitrate/nitrite colorimetric assay kit (Cayman Chemicals , Ann Arbor, MI, 
USA). 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Animals 
Male C57BL/6 mice (20–30 g) were purchased from Harlan (Bicester, UK). eNOS knock-out mice 
(eNOS-/-, Strain: 0026847) were purchased from Jackson Laboratory (Bar Harbor, ME, USA ) and bred 
in-house. Protocols involving the use of animals were licensed by the UK Home Office and approved 
by the Ethical Review Panel at Imperial College London. Procedures involving animals were 
conducted and are reported in accordance with ARRIVE guidelines [24]. 
 
Ozone chemiluminescence 
Wild-type or eNOS-/- mice were pre-treated with saline or sodium nitrate 1 h before they were 
anaesthetised and plasma and salivary glands extracted [25]. 1 h has previously been shown to 
provide adequate time for increases in plasma nitrate/nitrite following i.p. or oral administration of 
inorganic nitrate [18, 26, 27]. All samples were snap frozen and stored at -80°C until further analysis. 
Mouse salivary glands were homogenised with phosphate-buffered saline, using a Mixer Mill MM 
400 homogeniser, vibrational frequency 30 Hz (1800 min -1) for 3 mins.  Salivary gland homogenates 
or plasma were deproteinised by incubation with sodium hydroxide (0.5 M) and zinc sulphate (10% 
w/v) for 15 mins at room temperature.  Samples were centrifuged and the supernatant was 
extracted and analysed for nitrate/nitrite concentration using a Sievers nitric oxide analyser (280, 
Analytix).  Samples were refluxed in vanadium III chloride (0.1 M) and hydrochloric acid (1 M) at 95°C 
(nitrate analysis) or in sodium iodide (0.3 M) and glacial acetic acid at 35°C (nitrite analysis). 
Nitrate/nitrite concentrations were detected using ozone chemiluminescence as previously reported 
[28].  
In vivo platelet aggregation 
Platelets were isolated from wild-type or eNOS-/- donor mice and radiolabelled with 1.8 MBq indium 
oxine (In111) as previously described [29]. Radiolabelled platelets of the same genetic background 
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were administered to anaesthetised (urethane 25% w/v, 10 l g-1) recipient wild-type or eNOS-/- mice  
via the femoral vein and platelet aggregation responses were measured as increases in platelet-
associated counts in the pulmonary vascular bed following intravenous injection of collagen (50 g 
kg-1). In a typical experiment, 5 donor mice were bled and the resulting platelet pool evenly 
distributed into 4 recipient mice. The experimental protocol for sodium nitrate involved the pre-
treatment of the recipient mice with saline (0.9% w/v) or sodium nitrate (1 mmol kg-1, i.p) 1 h before 
collagen and sildenafil involved the administration of vehicle (DMSO <0.05%) or sildenafil (50 g kg-1, 
i.v) 5 mins before collagen. 
 
Data analysis and statistics 
All data were expressed as mean ± standard error of the mean (SEM). In vivo platelet aggregation 
data was expressed as the percentage increase in maximal radioactive counts from the baseline 
recording. In vitro platelet aggregation data were arbitrary ‘area under the curve’ values generated 
by the Aggrolink software (version 5.2.1, Chrono-log, Havertown, USA). All statistical tests were 
performed on raw data. Where statistical comparisons were made, Student’s t-test, one-way analysis 
of variance (ANOVA) or a two-way ANOVA followed by a Bonferroni post-hoc multiple comparison 
test were used to compare mean values. P-value < 0.05 was considered to denote statistical 
significance. 
 
Results 
Sildenafil inhibits platelet aggregation in vitro and in vivo 
We investigated the presence of a functionally relevant, intrinsic NO-cGMP signalling cascade in 
isolated human platelets by enhancing transient cGMP signals via inhibition of PDE5. The selective 
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PDE5 antagonist sildenafil (10-1000 nM) caused a significant and concentration-dependent inhibition 
of collagen- (Fig 1A-B) and thrombin-induced washed platelet aggregation in vitro (Fig 1C) but had no 
effect on ADP-induced aggregation (Fig 1D). In vivo, collagen-induced platelet aggregation was 
significantly reduced following pre-treatment of mice with 50 g kg-1 sildenafil (Fig 1 E-F).  
 
Sildenafil selectively amplifies endogenous NO-mediated signalling independent of NOS 
Sildenafil (10 nM) significantly enhanced NO-mediated inhibition of platelet aggregation (Fig 2A) but 
in contrast had no effect upon the inhibitory effect exerted by the prostacyclin mimetic iloprost (Fig 
2B). Sildenafil also induced a concentration-dependent increase in VASP-239P phosphorylation (Fig 
1C-D) when applied to isolated platelets.  Sildenafil-mediated inhibition of platelet aggregation was 
abolished in the presence of the sGC antagonist ODQ (1H-[1,2,4]Oxadiazolo[4,3-a]quinoxalin-1-one; 
Fig 2E) and the NO scavengers haemoglobin and hydroxocobalamin (Fig 2F).  In contrast, pre-
treatment of platelets with the NOS inhibitor L-NAME had no effect on sildenafil-mediated inhibition 
of aggregation compared to both vehicle and D-NAME control (2G). Similarly, sildenafil-mediated 
VASP-P239 phosphorylation was abolished by ODQ but not significantly affected by L-NAME (Fig 2H-
I).  
 
Nitrite reduction drives cGMP-mediated inhibition of platelet aggregation 
Having shown that isolated platelets generate inhibitory NO-cGMP signals that arise predominantly 
from sources other than NOS, we explored the ability of nitrate and nitrite to drive NO-cGMP-
mediated inhibition of platelet aggregation. We firstly demonstrated the presence of both nitrate 
and nitrite in platelet extracts and undetectable levels in experimental buffers using a colorimetric 
assay (Fig 3A). Washing of platelet suspensions with the mild reducing agent ascorbic acid lowered 
their nitrate and nitrite content presumably due to chemical reduction to NO (Fig 3B). Nitrate/nitrite 
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depletion and any accompanying NO release were associated with inhibition of platelet aggregation 
(Fig 3C). The inhibitory effect of nitrate/nitrite reduction by ascorbic acid was abolished by ODQ and 
haemoglobin (Fig 3D). 
Sodium nitrite (0.01 – 100 M) exerted a concentration-dependent inhibition of aggregation in the 
presence of sildenafil (Fig 3E) whereas equivalent concentrations of sodium nitrate had no effect (Fig 
3F.) The inhibitory effect of nitrite was abolished by ODQ and did not occur in the absence of 
sildenafil (Fig 3E). Similarly, nitrite increased VASP-P239 phosphorylation in the presence of sildenafil, 
an effect that was prevented by ODQ, whereas nitrate had no effect (Fig 3G-H). 
 
Inorganic nitrate inhibits platelet aggregation following enhanced bioconversion to nitrite during 
endothelial dysfunction in vivo 
Sodium nitrate (1 mmol kg-1) administration to mice led to increased concentrations of nitrate in 
salivary glands (Fig 4A) and increased plasma nitrate concentration (Fig 4B) in wild-type and eNOS-/- 
mice as measured by ozone chemiluminescence. There was also an accompanying increase in plasma 
nitrite that was not significant in wild-type mice but was significantly increased in eNOS-/- mice 
compared to saline-treated controls (Fig 4C). Nitrate administration had no significant effect on 
subsequent collagen-induced platelet aggregation in vivo in wild-type mice but significantly reduced 
platelet aggregation in eNOS-/- mice (Fig 5A-B).  
 
Discussion 
Sildenafil has already been shown to amplify the inhibitory effect of exogenously applied NO upon 
human platelet aggregation [4] and to reduce ADP-induced glycoprotein IIb/IIIa activation [30] and 
aggregation [5] ex vivo indicating the ability of sildenafil to enhance the platelet inhibitory activity of 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
exogenous and endothelial NO respectively. The ability of sildenafil to enhance intrinsic endogenous 
NO signals in platelets is less well studied although a lack of effect upon ADP-induced aggregation has 
been reported [6]. We found a similar lack of effect when platelets were stimulated with ADP in the 
absence of exogenous NO but, in contrast, found an inhibition of collagen- and thrombin-induced 
aggregation in isolated platelet suspensions. This finding indicates, not only the ability of sildenafil to 
directly modulate platelet activation in the absence of exogenous or endothelial NO, but 
demonstrates the presence of transient, endogenous signals upstream of PDE5 in platelets. The 
ability of sildenafil to modulate activation downstream of collagen and thrombin suggests 
modulation of pathways that were not triggered by the relatively weaker agonist ADP. In addition, 
experiments with ADP in work published previously [6] and in the current study were conducted in 
the presence of plasma proteins whereas experiments with collagen and thrombin were conducted 
in preparations lacking plasma proteins. The lack of effect of sildenafil in ADP experiments may 
therefore be partially pharmacokinetic due to interaction of relatively lipophilic sildenafil [31] with 
plasma proteins. 
 
We confirmed that, in isolated platelets, sildenafil acts downstream of the NO-cGMP signalling 
cascade by showing that its inhibitory effects were completely abolished by the sGC antagonist ODQ 
and two distinct NO scavengers. We further confirmed that sildenafil mediates inhibitory signalling 
events in platelets by demonstrating phosphorylation of VASP at Ser239.  Given the reported cross-
talk between cyclic nucleotides and PDEs [32], particularly at the level of protein kinases [33, 34], we 
contrasted the selectivity of sildenafil upstream of these signalling events and showed an ability of 
sildenafil to enhance the inhibitory effect of NO (Fig 2A) but not prostacyclin (Fig 2B). Sildenafil 
therefore selectively amplifies the inhibitory effect of NO with no measurable functional effect on 
prostacyclin-mediated inhibition despite downstream crosstalk between these pathways. 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
A number of groups, including ours, have previously suggested a lack of functional relevance or 
expression of NOS in human platelets [13, 14]. This led us to consider the source of NO acting 
upstream of sildenafil to mediate inhibition of platelet aggregation. Studies with a NOS inhibitor (Fig 
2G) suggested that the effect of sildenafil occurred independently of NOS suggesting alternative 
sources of bioactive NO. The validity of this conclusion depends upon effective blockade of NOS at 
the concentration of L-NAME employed. L-NAME inhibits NOS with an IC50 of 0.81 M [35] and off-
target effects in platelets emerge at around 500 M to 1 mM [14]. Our working concentration of 100 
M can therefore be reasonably assumed to result in effective and selective inhibition of NOS activity 
in platelets as previously reported [36]. Nonetheless, although we have data suggestive of NOS-
independent inhibitory activity upstream of PDE5, we cannot exclude entirely the possibility that NO 
derived from NOS, if expressed in platelets, may have relevance under certain circumstance, albeit 
insignificant in the present study. We proceeded by exploring the ability of inorganic nitrate and 
nitrite (administered as sodium nitrate and sodium nitrite) to modulate platelet activation and VASP 
phosphorylation. 
 
 In mammals, inorganic nitrate can be bioconverted to nitrite and subsequently reduced to NO by a 
variety of mechanisms [20, 37, 38].  We firstly confirmed that platelets contain nitrate/nitrite that 
could potentially be reduced to NO to explain the presence of endogenous, NOS-independent NO 
signals in platelets. Nitrate and nitrite levels in platelets were then successfully depleted by 
incubation of platelets with the mild and relatively non-toxic reducing agent ascorbic acid in buffer 
prepared with nitrate free water. We hypothesised that reduced endogenous nitrite would generate 
a NO/cGMP signal that could be amplified by sildenafil to inhibit agonist induced aggregation and 
found evidence to support this when ascorbic acid induced ODQ-sensitive inhibition of aggregation. 
In fact, the inhibitory effect of ascorbic acid was entirely abolished by ODQ or NO scavenging 
suggesting that, under the prevailing experimental conditions, ascorbic acid exerted functional 
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effects that were entirely mediated via sGC and NO. Reducing agents exert a range of effects 
including reduction of reactive oxygen species and peroxynitrite and demonstrating that reducing 
agents can drive inhibitory signalling, whilst indicating that, in principle, platelet function can be 
impacted by reduced nitrite/nitrate, does not demonstrate an endogenous ability of platelets to 
reduce nitrate or nitrite to NO. We therefore investigated the functional impact of nitrate/nitrite in 
the absence of exogenous reducing agents to directly link nitrate/nitrite with platelet activity. Nitrite 
has previously been reported to directly inhibit platelet aggregation although the concentrations 
required were higher than those found in plasma following nitrate administration to humans [21, 
39]. In contrast, lower, more relevant concentrations of nitrite were shown to have no effect on 
isolated platelets [22] reflecting either an inability of platelets to reduce nitrite or the generation of a 
transient signal without functional impact. The application of a fixed concentration of sildenafil in the 
current study revealed the ability of nitrite but not nitrate to generate ODQ-sensitive inhibitory 
signals in platelets in the presence of sildenafil suggesting an endogenous capacity to reduce nitrite. 
In line with earlier studies [22], nitrite had no effect on platelet aggregation in the absence of 
sildenafil suggesting the generation of transient signals which are, under normal circumstances, 
rapidly hydrolysed by PDE5. Although some evidence of sGC-independent effects of NO [40-42] has 
been reported, the effects of nitrite reported here are entirely-sGC dependent. This is in line with 
more recently reported data demonstrating absolute dependence of NO-mediated signalling upon 
sGC in platelets [43]. The mechanism by which platelets reduce nitrite remains unclear. In other cell 
types such as vascular endothelial cells, nitrite is reduced enzymatically by xanthine oxidases [17, 20] 
and aldehyde dehydrogenase [44], however these enzymes are not part of the platelet proteome 
[45]. In addition, nitrite reduction is also suggested to occur in erythrocytes [22, 46, 47], implying an 
enhanced capacity to reduce nitrite in whole blood and in vivo compared with isolated platelets or 
plasma.  Therefore, alternative mechanisms in platelets such as mitochondrial activity or the 
presence of as yet unidentified mediators with reducing capacity may explain the efficacy of nitrite in 
isolated platelets reported here. Given the absence of many of the proposed nitrate reductase 
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systems from platelets, we tentatively speculate that the most likely mechanism of nitrite reduction 
in platelets to be a mitochondrial nitrite reductase such a cytochrome C [48]. Demonstrating 
conclusively the role of mitochondrial components with critical roles in mitochondrial respiration and 
cellular metabolism in nitrite reduction and inhibition of platelet activation is likely to be challenging. 
The presence of NOS in platelets has been contentious for some time now [11, 12] and there is 
increasing evidence of a lack of importance of NOS-derived NO in regulating platelet function [13, 14] 
(the primary source of NO affecting platelets physiologically being the vascular endothelium [7]). 
Nonetheless, platelets are widely reported to generate NO [15, 16]. Our data provide one potential 
explanation of these apparently contradictory observations in addition to those previously suggested 
such as NO production via s-nitrosothiols [49] and protein disulphide isomerases [50]. 
 
We also explored the in vivo relevance of our data obtained with isolated platelets. Sildenafil has 
previously been reported to improve coronary artery patency in a model of cyclic coronary occlusion 
[51]. The effect was suggested to be potentially platelet-mediated but may also have been due to 
coronary vasodilation. The model used in the current study was selected because it has previously 
been shown to measure platelet aggregation independent of any effect on vascular tone [7]. We can 
therefore conclude that as well as exerting a direct inhibitory effect upon platelets in vitro, sildenafil 
inhibits agonist induced platelet aggregation in vivo via a direct effect upon the platelet rather than 
via a secondary vascular effect. Since in vivo preparations contain a fully functional vascular 
endothelium, it is reasonable to conclude that the effect of sildenafil upon platelets in vivo is at least 
in part mediated via enhancement of NO derived from the vascular endothelium as well as via any 
direct platelet-mediated effect of nitrite. 
Nitrate administration in humans has previously been shown to induce a fall in blood pressure and to 
inhibit ex vivo platelet aggregation [21, 22]. In previously reported mouse studies, a lowering of 
plasma nitrite concentration was associated with enhanced platelet aggregation ex vivo [52]. 0.2 
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mmol kg-1 d-1 of nitrate has been estimated to be produced endogenously by NOS [26, 53]. One 
nitrate-rich vegetable portion contains more nitrate that that produced by all forms of NOS daily 
[54]. Therefore the dose of 1 mmol kg-1 nitrate used in the current study reflects a realistic dose that 
could be achieved through dietary choices or supplementation. In the present study, the increase in 
plasma nitrite concentration following administration of nitrate to wild-type mice, although not 
significant, was similar to that reported previously in humans following consumption of high nitrate 
beetroot juice (approximately 0.2 M) [21]. This increase in plasma nitrite did not lead to a change in 
platelet aggregation in situ in our study suggesting that NO was not a limiting factor in the context of 
a healthy vasculature. In eNOS-/- mice however, nitrate administration led to an approximately 5-fold 
greater increase in plasma nitrite (approximately 1 M) indicating that bioconversion of nitrate to 
nitrite was certainly evident and indeed greater than that observed in wild-type mice . These data 
suggest that eNOS-/- mice may compensate for the absence of NO from conventional enzymatic 
sources by increasing NO generation from nitrate. Our data showing nitrate reduction in eNOS-/- mice 
also indicate that although eNOS has been shown to mediate nitrite reduction in a previous 
study[55], this was not a primary mechanism of systemic reduction in our study. Our data raise the 
question of whether a similar switch in the physiological source of NO from NOS to nitrite occurs in 
humans with vascular disease. This issue has not been addressed in the current study and additional 
studies in humans and, in particular, patients with cardiovascular conditions associated with deficient 
eNOS activity are required to translate our mechanistic linking of eNOS with enhanced nitrite 
reduction to human pathology. If this translation were established, then nitrate/nitrite derived from 
the diet may become critical as a source of bioactive NO during endothelial dysfunction. We tested 
the functional relevance of the differential changes in plasma nitrite in wild-type and eNOS-/- mice by 
measuring platelet aggregation in vivo. Interestingly, the higher bioconversion of nitrate occurring in 
eNOS-/- mice was associated with a significant reduction in platelet aggregation, an effect not seen in 
wild-type mice. Our data therefore suggest that nitrate exerted a specific effect upon platelet 
function during conditions of vascular dysfunction, namely eNOS deficiency, whilst during vascular 
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health, associated with wild-type mice, normal platelet function was retained. This data is potentially 
of great interest since it suggests targeted efficacy during conditions of endothelial dysfunction. In 
summary, we have shown that platelets generate transient, endogenous cGMP signals that may be 
pharmacologically enhanced by inhibition of PDE5 activity. These signals are generated downstream 
of NO but are primarily independent of NOS activity. Furthermore, nitrite is able to generate 
transient NO-cGMP signals in platelets which can be enhanced by sildenafil. The absence of eNOS 
leads to an enhanced capacity to bioconvert nitrate to nitrite which in turn negatively impacts 
platelet function. Our study adds to the increasing body of evidence suggesting that dietary nitrate 
may account, at least partly, for the beneficial effects of healthy diets, particularly those rich in green 
vegetables with high nitrate content. Furthermore, inorganic nitrate may potentially exert an 
antiplatelet effect specifically during endothelial dysfunction whilst allowing retention of normal 
platelet function in conditions of vascular health. Our study, when combined with growing literature 
concerning the impact of dietary nitrate on cardiovascular health, suggests that the potential use of 
dietary nitrate supplementation in the primary prevention of platelet-driven cardiovascular events 
should be further explored. 
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Figure Legends 
Figure 1: Sildenafil inhibits platelet aggregation in vitro and in vivo. A - D: Isolated human platelets 
were pre-incubated with vehicle or sildenafil citrate (10 nM - 1 µM) for 5 mins before stimulation 
with (A-B) collagen (5 µg mL-1), (C) thrombin (0.1 U mL-1) and (D) adenosine diphosphate (ADP, 0.3 – 
30 µM). Platelet aggregation was measured as light transmission. (A) Example traces are 
representative of 8 independent experiments. (B-C) Data are expressed as mean±S.E.M. One-way 
ANOVA with Bonferroni post-hoc test, *P<0.05, **P<0.01, ***P<0.001 compared to vehicle (D) 
Vehicle EC50 = 0.585 µM, sildenafil EC50 = 0.447 M. E - F: Sildenafil (50 µg kg-1) or vehicle was 
administered to mice 5 mins before collagen (50 µg kg-1). Platelet aggregation was measured as 
changes in radioactive counts in the pulmonary vasculature. (E) Mean trace of collagen response is 
expressed as percentage increase from baseline, error bars omitted for clarity. (F) Maximum 
percentage increase from baseline is expressed as mean ± S.E.M., unpaired Students t-test, *P<0.05 
compared to vehicle, n=5-8. 
Figure 2: Sildenafil selectively amplifies endogenous NO-mediated signalling independent of nitric 
oxide synthase (NOS). A-B: Sildenafil (10 nM) significantly enhanced the inhibition of collagen-
induced (5 µg mL-1) washed human platelet aggregation mediated by (A) SNP (0.01-100 µM), but not 
(B) iloprost (0.1-1000 pM). C-D: sildenafil (10 – 1000 nM) and SNP (positive control) induced 
phosphorylation of VASP at serine 239 (VASP-239P). Data are shown as (C) Western blot 
representative of 4 independent experiments, (D) percentage of VASP-239P compared to total VASP. 
Data are expressed as mean±S.E.M. E-G: The inhibitory effect of sildenafil (10 nM – 1 µM) on 
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collagen-induced aggregation was significantly inhibited by (E) ODQ (10 µM) and (F) haemoglobin 
(Hb, 5 µM) or hydroxocobalamin (HXB, 100 µM), whereas (G) L-NAME (100 µM) or D-NAME (100 µM) 
had no effect. H - I: sildenafil (100 nM) induced VASP-239P phosphorylation was abolished by ODQ 
whereas L-NAME had no effect, data are presented as (H) Western blot representative of 4 
independent experiments and (I) percentage of VASP-239P compared to total VASP. Data are 
expressed as mean±S.E.M., One-way ANOVA with Bonferroni post-hoc test, *P<0.05, **P<0.01, 
***P<0.001 compared to vehicle treated, ns = not significant (P>0.05) compared to sildenafil treated, 
n=4-6. 
Figure 3: Nitrite drives cGMP-mediated inhibition of platelet aggregation. A-B: Nitrate and nitrite 
concentration was measured in human platelets (A) untreated or (B) pre-incubated with vehicle or 
ascorbic acid (10, 1000 µM). Data are expressed as mean±S.E.M, one-way ANOVA with Bonferroni 
post-hoc test. C: Collagen (5 µg mL-1) induced aggregation was inhibited in nitrate/nitrite depleted 
platelets treated with ascorbic acid, one-way ANOVA with Bonferroni post-hoc test. D: Ascorbic acid-
induced (2.5mM) inhibition of aggregation was reversed in the presence of ODQ (10 µM) and 
haemoglobin (Hb; 5µM), one-way ANOVA with Bonferroni post-hoc test. E-F: Sodium nitrite (NaNO2, 
0.01-100 µM) caused concentration-dependent inhibition of platelet aggregation in the presence of 
sildenafil (10 nM) which was reversed by ODQ (10 µM), an effect not seen with (F) sodium nitrate 
(NaNO3, 0.01-100 µM). Data are expressed as mean±S.E.M, two-way ANOVA with Bonferroni post-
hoc test. G-H: Pre-incubation of platelets with NO2 (100 µM) and sildenafil (10 nM) resulted in 
significant phosphorylation of VASP at serine 239 (VASP-239P) that was reversed in the presence of 
ODQ (10 µM). This effect was not seen with NO3 (100 µM). Sodium nitroprusside (SNP, 1 µM) was 
used as a positive control. Data are presented as (G) Western blot representative of 4 independent 
experiments and (H) percentage of VASP-239P compared to total VASP. Data are expressed as 
mean±S.E.M., one-way ANOVA with Bonferroni post-hoc test. *P<0.05, **P<0.01, ***P<0.001 
compared to vehicle treated, n=4-7. 
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Figure 4: Bioconversion of nitrate to nitrite is enhanced in the absence of eNOS. A-B: Following 
treatment of mice with saline or sodium nitrate (1 mmol kg-1 i.p.) for 1 h, nitrate concentrations were 
significantly increased in (A) salivary glands and (B) plasma in both wild-type (W.T) and eNOS-/- mice. 
C: Plasma nitrite concentration was significantly increased in eNOS-/- but not W.T. mice following 
nitrate treatment. Data are expressed as mean±S.E.M., unpaired Students t-test, *P<0.05, **P<0.01, 
***P<0.001, ns= non-significant (P>0.05), n=5-7. 
Figure 5: Inorganic nitrate inhibits platelet aggregation during endothelial dysfunction in vivo. Wild-
type (W.T) and eNOS-/- mice were treated with saline or sodium nitrate (1mmol kg-1 i.p.) 1 h prior to 
collagen (50 µg kg-1) and radiolabelled platelet aggregation was measured as changes in radioactive 
counts in the pulmonary vasculature. A: Mean trace of collagen response (percentage increase from 
the baseline radioactive counts) versus time. Data are expressed as mean (error bars omitted for 
clarity). B: Maximum percentage increase from baseline radioactive counts. Data are expressed as 
mean ± S.E.M., unpaired Students t-test, *P<0.05, ns = non-significant (P>0.05), n=4-6. 
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